Home/Pipeline/oNKord® (Inaleucel)

oNKord® (Inaleucel)

Acute Myeloid Leukemia (AML)

Phase 1/2aActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2a

Status

Active

Company

Glycostem

About Glycostem

Glycostem Therapeutics is a pioneering developer of allogeneic, off-the-shelf NK cell immunotherapies derived from umbilical cord blood stem cells. Its core technology platform enables the production of highly pure, safe, and cost-effective NK cell products, with a lead candidate, oNKord®, in a pivotal Phase I/IIa trial for AML. The company has established a strategic partnership with medac GmbH for commercialization and is expanding its pipeline to include next-generation CAR-NK and other engineered NK cell therapies targeting both hematological and solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
NTLA-5001	Intellia Therapeutics	Phase 1/2	Active
Galinpepimut-S (GPS)	SELLAS Life Sciences	Phase 2/3	Active
SLS009 (GFH009)	SELLAS Life Sciences	Phase 1/2	Active
UCART123	Cellectis	Phase 1	Active
Iadademstat (ORY-1001)	Oryzon Genomics	Phase 2	Active - Combination with azacitidine
MP0533	Molecular Partners	Phase 1/2	Active
SEL24 (MEN1703)	Selvita	Phase 1/2	Active
Selinexor	Karyopharm Therapeutics	Clinical Trials	Investigational
NEX-20 (azacitidine)	Nanexa AB	Phase 1	Active